POLICY & GOVERNMENT

President Joe Biden's recent executive order on artificial intelligence aims to enhance accountability in the development and deployment of AI technology.Industry leaders recognize AI's potential in healthcare for faster diagnosis, precisetreatments, drug development, and alleviating documentation challenges fordoctors. However, concerns persist about the current lack of regulations in the AI industry, prompting the need for essential regulations to address issues likeprivacy, security, safety, and equity, as emphasized in the executive order.

Cercle, a new A.I. company focusing on women's healthcare, has launched its Biomedical Graphplatform, utilizing A.I. to transform billions of deidentified biomedical and genomics data points intostructured insights for researchers and healthcare providers. The platform, the first of its kind, addressesthe challenge of analyzing up to 80% of unstructuredmedical data. Partnering with Eurofins Genoma and USFertility, Cercle aims to enhance in vitro fertilizationoutcomes and success rates while addressing the datagap in women's healthcare, with plans to expand support across various women's health verticals.

PROSTATE CANCER

According to a retrospective study published in European Urology Open Science, an A.I. deep learning model was found to be more effective in predictingnegative margins and focal treatment margins inresected prostate cancer specimens than conventional models. The A.I.-derived margins produced a meansensitivity of 96.9% compared to 37.4% for conventional Prostate Imaging Reporting and Data System regions of interest (ROI). Additionally, the A.I. model was more effective in reducing the extent of missed clinically significant prostate cancer.

CLINICAL DECISION MAKING

Hims & Hers Health, Inc. has launched a new technology called MedMatch which leverages millions ofanonymized data points from millions of customers in real-time. MedMatch is initially being deployed forcustomers seeking support for anxiety and depression.The technology is designed to help providers identify the optimal treatment for a particular person byrecommending clinical decisions and treatmentsinformed by the collective knowledge of thousands of providers and millions of data points.

WOMEN’S HEALTH

Royal Philips has received an additional $44.6 million from the Bill and Melinda GatesFoundation, bringing total funding to $60 million for the global deployment of its AI enabled Lumify Ultrasound System. Initially granted$15.4 million in 2021, Philips developed the A.I. to aidfrontline health workers in identifying pregnancycomplications, particularly in underservedcommunities, with a successful trial conducted in Kenya. The new funding aims to expand global adoption

CARDIOLOGY

To address the challenge of early misdiagnosis in progressive diseases like pulmonary hypertension(PH) and cardiac amyloidosis, Johnson & Johnsoncollaborates with Anumana, Mayo Clinic, UltromicsLtd., and Atman Health to develop A.I. algorithms.These algorithms, integrated into the clinicalworkflow, analyze common diagnostic tests(electrocardiograms for PH and echocardiogramsfor cardiac amyloidosis) to detect subtle indicatorsinvisible to the naked eye. Both the PH and cardiac amyloidosis algorithms have received Breakthrough Device Designation from the U.S. FDA, potentially enabling earlier and more accurate diagnoses for timely patient treatment.